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Background: Although the role of microRNA’s (miRNA’s) biogenesis pathway genes in cancer development and
progression has been well established, the association between genetic variants of this pathway genes and breast
cancer survival is still unknown.
Methods: We used genotype data available from a previously conducted case–control study to investigate
association between common genetic variations in miRNA biogenesis pathway genes and breast cancer survival.
We investigated the possible associations between 41 germ-line single-nucleotide polymorphisms (SNPs) and both
disease free survival (DFS) and overall survival (OS) among 488 breast cancer patients. During the median follow-up
of 6.24 years, 90 cases developed disease progression and 48 cases died.
Results: Seven SNPs were significantly associated with breast cancer survival. Two SNPs in AGO2 (rs11786030 and
rs2292779) and DICER1 rs1057035 were associated with both DFS and OS. Two SNPs in HIWI (rs4759659 and
rs11060845) and DGCR8 rs9606250 were associated with DFS, while DROSHA rs874332 and GEMIN4 rs4968104 were
associated with only OS. The most significant association was observed in variant allele of AGO2 rs11786030 with
2.62-fold increased risk of disease progression (95% confidence interval (CI), 1.41-4.88) and in minor allele
homozygote of AGO2 rs2292779 with 2.94-fold increased risk of death (95% CI, 1.52-5.69). We also found cumulative
effects of SNPs on DFS and OS. Compared to the subjects carrying 0 to 2 high-risk genotypes, those carrying 3 or
4–6 high-risk genotypes had an increased risk of disease progression with a hazard ratio of 2.16 (95% CI, 1.18- 3.93)
and 4.47 (95% CI, 2.45- 8.14), respectively (P for trend, 6.11E-07).
Conclusions: Our results suggest that genetic variants in miRNA biogenesis pathway genes may be associated with
breast cancer survival. Further studies in larger sample size and functional characterizations are warranted to
validate these results.
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Breast cancer is the most common cancer among
females and represents 14% of female cancer deaths
worldwide [1]. In Korea, breast cancer is the second
most common cancer comprising 14.7% in year 2008
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reproduction in any medium, provided the origduring the last 6 years. The age-specific incidence rates
of breast cancer among Korean women are somewhat
different from those of western country, showing their
highest peak in the 45–49 years age group with the pro-
portion of young age-onset breast cancer much higher
than in western countries [2-4]. While breast cancer in-
cidence has increased over the past 30–40 years, mortal-
ity has remained stable or even decreased in the last 10–
15 years, a likely result of earlier detection and improved
treatment strategy. [5]. However, breast cancer survival
can vary considerably not only among different ethnictd. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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cer. These differences have been partially explained by
the traditional prognostic and predictive factors related
to clinical and pathological features of breast cancer [6].
Previous studies conducting candidate gene approach
and recently added genome-wide association studies
have implicated inherited factors as influences on breast
cancer survival. However, the reported effect size was
very small to moderate and do not fully explain the het-
erogeneity in breast cancer survival [7-9].
MicroRNAs (miRNAs) are a major class of endogen-
ous short non-coding RNAs that post-transcriptionally
modulate gene expression in a sequence specific manner
[10]. The role of miRNAs in human cancer pathogenesis
has been well established by the identification of aber-
rant expression of miRNAs in many types of cancer in-
cluding breast cancer [11]. It is also suggested that the
perturbations in miRNA expression facilitate the key
pathways involved in cancer progression such as inflam-
mation, cancer cell invasion, angiogenesis, and metasta-
sis [12]. Some miRNAs were reported to be associated
with invasive and metastatic phenotype of breast cancer
cell lines and to be also correlated with metastatic tumor
tissues as well. On the other hand, some miRNAs serve
as metastasis suppressors and it was shown that their ex-
pression is frequently downregulated or lost in both
breast cancer cell lines and metastatic foci [13].
There is increasing evidence that the presence of gen-
etic variants in precursor or mature miRNAs, their bio-
genesis pathway genes, or in miRNA binding sites of
target mRNA are associated with the risk of cancer de-
velopment [14]. More recently, the effects of genetic var-
iants in miRNA related genes have been demonstrated
to be associated with cancer survival in several types of
cancers including colorectal cancer [15], renal cell car-
cinoma [16], ovarian cancer [17] and head and neck can-
cer [18].
Although the role of miRNA’s biogenesis pathway
genes in cancer development and its progression has
been well established, the association between genetic
variants of this pathway genes and breast cancer survival
is still unknown. Here, we selected 41 SNPs in 14 candi-
date genes (AGO1, AGO2, DICER1, DGCR8, DROSHA,
FMR1, GEMIN3, GEMIN4, HIWI, RAN, TARBP2, XPO5,
p68 and p72) involved in the canonical miRNA biogen-




The REMARK criteria was used to report our data [21].
The study subjects were derived from the previous study
to investigate association between the polymorphisms in
miRNA biogenesis pathway genes and breast cancer risk[22]. The description of the Seoul Breast Cancer Study
(SeBCS) has been described in the previous study.
Briefly, histologically confirmed breast cancer cases
(n = 3,497) and controls (n = 1,273) were recruited by the
Seoul National University Hospital and Asan Medical
Center between 2001 and 2007. A questionnaire was
given by the trained interviewers to collect information
on demographic, reproductive and other lifestyle factors.
Peripheral blood was drawn into 10-mL heparinized
tubes and stored at −70°C until genotyping. Those with
previous history of cancer (n = 156), previous history of
hysterectomy or oophorectomy (n = 268) were excluded.
After the additional exclusion of the subjects with no or
insufficient DNA samples (n = 760), 559 patients were
available for genotyping experiment. Patients were fol-
lowed up to March 2010 using a retrospective chart re-
view with standard protocol to collect clinicopathological
features, patients’ treatments, and vital status such as re-
currence and death. The vital status was additionally
checked through the death registry of the Korea National
Statistical Office in May 2011.
Patients diagnosed with in situ breast cancer (n = 49),
benign breast cancer (n = 13), or multiple cancer at diag-
nosis (n = 2) and with incomplete linkage of both clinical
record and death record due to error in resident regis-
tration number (n = 7) were additionally excluded for
survival analysis. Thus, a total of 488 invasive breast
cancer patients were included in the final analysis. The
baseline characteristics by study inclusion were pre-
sented in Additional file1: Table S1.
Informed consents were received from every patient
when the questionnaire was administered. The study de-
sign was approved by the Committee on Human Re-
search of Seoul National University Hospital (IRB No.
H-0503-144-004).
SNP selection and genotyping
The selection of genes and SNPs has been previously
described in detail [22] . Using the data from the Inter-
national HapMap Project (http://www.hapmap.org/),
dbSNP (NCBI, http://www.ncbi.nlm.nih.gov/projects/
SNP/) and web-based SNP selection tools (http://www.
niehs.nih.gov/snpinfo) [23], we selected 41 haplotype
tagging SNPs (htSNPs) defined by the linkage disequilib-
rium (LD) with square of the pairwise correlation coeffi-
cient, r2> 0.90, in the genomic region from 5 kb
upstream and 3 kb downstream of the largest cDNA iso-
form of each gene with minor allele frequency (MAF) of
> 0.05 in Asian populations; 35 SNPs in 12 genes in
miRNA biogenesis pathway and 6 SNPs in 2 genes
involved in hormonal regulation of miRNA biogenesis.
To measure the LD between SNPs, LD parameters (r2
and D′) were calculated using Haploview version 4.2
software (Whitehead Institute, Cambridge, MA, http://
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case of multiple potentially functional SNPs within the
same haplotype block, only one SNP was included in
our analyses. The proportion of common variants tagged
with r2 more than 0.8 ranged from 32.4% to 100% [22] .
Genotyping for 41 SNPs was conducted using the Taq-
Man assay (Applied Biosystems, Carlsbad, California). Pri-
mers and probes are available upon requests from the
authors. Randomly selected 5% of samples and negative
controls were included to ensure the accuracy of genotyp-
ing. The concordance rates for quality-control samples
were >95.0% for all assays. For all 41 SNPs investigated, no
significant deviation from Hardy-Weinberg equilibrium
was observed among the controls (P> 0.01). We discarded
one SNP in TARBP (rs2280448) that showed minor allele
frequency less than 5%.
Statistical analyses
The differences in patient characteristics by study inclu-
sion were assessed by the Pearson’s χ2 tests for categor-
ical variables and the Student's t-test for continuous
variable.
The primary outcomes were disease-free survival
(DFS) and overall survival (OS). For DFS analysis, we
only included patients with stage I-III (n= 480) exclud-
ing patients diagnosed with stage IV (n= 8). DFS time
was defined as the time from the date of surgery until
the date of the first locoregional recurrence, first distant
metastasis, 2nd primary cancer or death from any cause.
Patients known to be alive with no evidence of disease
progression were censored at the last follow-up date or
31 March 2010, whichever came first. OS time was
defined as the time from diagnosis until the date of
death from any cause, censoring at the date of the last
follow up or 31 May 2011, whichever came first.
Kaplan-Meier method was used to estimate the sur-
vival function, and differences across survival curves
were examined using log-rank test. For the DFS analysis,
Cox’s proportional hazard regression models were used
to estimate hazard ratios (HR) and 95% confidence inter-
vals (CI) adjusting for age at diagnosis, tumor size
(≤ 2 cm and> 2 cm), lymph-node involvement (no and
yes), histologic grade (I-II and III), nuclear stage (I-II
and III), estrogen receptor (ER) status (positive and
negative), progesterone receptor (PR) status (positive
and negative), and hormone receptor therapy (yes and
no) in the final model. For the OS analysis, tumor size
(≤ 2 cm and> 2 cm), lymph-node involvement (no and
yes), distal organ metastasis (no and yes), histologic
grade (I-II and III) and hormone receptor therapy (yes
and no) were included in the final model. Other covari-
ates considered but not included the final model were
menopausal status, adjuvant chemotherapy, and radio-
therapy. Because these variables did not alter HRssignificantly after adjusting for other covariates (statis-
tical significance for the inclusion of the final model was
set at P< 0.20) and the final model adjusted for all the
covariates made no substantial difference to the results.
The significance of the full versus reduced model was
calculated with an F-test.
The proportional hazard assumption of the Cox model
was examined by graphic evaluation of Schoenfeld re-
sidual plot. We generated dummy variables indicating
the missing (1) and non-missing (0) for the all covariates
and all the missing values of covariates were coded as
‘-1’. When we tested the regression model, each covari-
ate was included in the model with respective dummy
variable for missingness so that all the patients were
included in the statistical models.
For individual SNP analysis, we tested three genetic
models (additive, dominant and recessive) to evaluate
the significance of SNPs and the best fitting model for
each SNP was selected by the smallest P value.
Given the number of SNPs investigated, the Benjamini-
Hochberg false discovery rate (FDR) method was used to
assess the statistical significance after correction for mul-
tiple comparisons. We considered FDR< 0.05 as being
noteworthy [24].
For haplotype analysis, the missing data with at least
one of five polymorphic sites were excluded. Assuming
HWE, the expectation-maximization algorithm was used
to calculate the maximum likelihood estimates of the
haplotype frequencies using SAS PROC HAPLOTYPE.
The haplotypes with frequencies less than 5% in all
patients were combined into one group. The most com-
mon haplotype was compared with other haplotypes
with adjustment for selected covariates. Haplotype data
were treated as categorical variable and were incorpo-
rated as dummy variables in the Cox model. Cumulative
effects of SNPs were assessed by counting the number of
high-risk genotypes in each subject. High-risk genotypes
were defined as the genotypes with risk conferring-allele
shown to be significantly associated with DFS or OS.
The number of high-risk genotypes was categorized as
low, medium, and high-risk groups and HRs and 95%
CIs were calculated for all groups and compared with
the low-risk group.
All statistical procedures were conducted using SAS
version 9.2 (SAS Institute, Cary, NC). All P values
reported were two-sided.
Results
The differences between the patients’ characteristics by
study inclusion were evaluated (Supplementary Table 1).
All the clinical characteristics compared were not signifi-
cantly different between two groups other than the dis-
tribution of age. The patients included in this study were
younger than those excluded from the study (mean
Table 1 Baseline characteristics of subjects by follow up status
Disease-free survival (n = 480) Overall survival (n = 488)
Relapse (n = 90)a No relapse (n = 389) HR (95% CI) P aHR (95% CI) b P Death (n= 41) Alive (n = 447) HR (95% CI) P aHR (95% CI) c P
Follow up duration, years (median) 0.12-8.34 (4.64) 0.18-9.45 (6.24)
Age (mean(SD)) 46.3 (12.5) 46.6 (10.6) 0.99 (0.97- 1.01) 0.470 1.00 (0.98- 1.02) 0.918 45.8 (13.8) 46.8 (10.7) 0.98 (0.96- 1.01) 0.289 0.99 (0.97- 1.02) 0.632
Tumor size
≤2 cm 27 (30.0) 210 (55.1) 1 (reference) 1 (reference) 10 (21.7) 229 (52.9) 1 (reference) 1 (reference)
>2 cm 63 (70.0) 171 (44.9) 2.49 (1.59- 3.91) <.001 1.66 (1.01- 2.72) 0.045 36 (78.3) 204 (47.1) 3.73 (1.85- 7.52) <.001 2.20 (1.03- 4.67) 0.041
Lymph-node involvement
No 36 (40.0) 258 (67.5) 1 (reference) 1 (reference) 15 (32.6) 282 (65.0) 1 (reference) 1 (reference)
Yes 54 (60.0) 124 (32.5) 3.00 (1.97- 4.58) <.001 2.54 (1.60- 4.03) <.001 31 (67.4) 152 (35.0) 3.86 (2.08- 7.16) <.001 2.70 (1.40- 5.20) 0.003
Metastasis
No 90 (100) 389 (100) - - - - 42 (91.3) 432 (99.1) 1 (reference) 1 (reference)
Yes 4 (8.7) 4 (0.9) 7.15 (2.55-20.02) <.001 5.26 (1.71-16.15) 0.004
Histologic grade
I-II 23 (30.7) 207 (61.4) 1 (reference) 1 (reference) 12 (31.6) 221 (58.3) 1 (reference) 1 (reference)
III 52 (69.3) 130 (38.6) 3.00 (1.84- 4.90) <.001 3.40 (1.74- 6.64) <.001 26 (68.4) 158 (41.7) 2.81 (1.42- 5.56) 0.003 1.93 (0.93- 4.03) 0.078
Nuclear grade
I-II 21 (40.4) 146 (59.4) 1 (reference) 1 (reference) 8 (34.8) 160 (57.1) 1 (reference) 1 (reference)
III 31 (59.6) 100 (40.7) 1.82 (1.05- 3.17) 0.034 0.59 (0.28- 1.23) 0.161 15 (65.2) 120 (42.9) 2.52 (1.07- 5.94) 0.035 1.12 (0.40- 3.11) 0.830
Estrogen receptor
Positive 49 (55.1) 238 (63.0) 1 (reference) 1 (reference) 22 (48.9) 269 (62.9) 1 (reference) 1 (reference)
Negative 40 (44.9) 140 (37.0) 1.33 (0.88- 2.03) 0.177 1.69 (0.79- 3.62) 0.177 23 (51.1) 159 (37.2) 1.82 (1.02- 3.28) 0.044 1.02 (0.37- 2.80) 0.975
Progesterone receptor
Positive 42 (47.7) 202 (53.6) 1 (reference) 1 (reference) 18 (40.0) 230 (54.0) 1 (reference) 1 (reference)
Negative 46 (52.3) 175 (46.4) 1.23 (0.81- 1.87) 0.331 1.53 (0.79- 2.96) 0.202 27 (60.0) 196 (46.0) 1.75 (0.96- 3.18) 0.066 1.14 (0.48- 2.73) 0.765
Adjuvant chemotherapy
Yes 78 (88.6) 285 (76.0) 1 (reference) 1 (reference) 41 (91.1) 327 (76.9) 1 (reference) 1 (reference)
No 10 (11.4) 90 (24.0) 0.47 (0.24- 0.91) 0.026 1.00 (0.47- 2.14) 0.996 4 (8.9) 98 (23.1) 0.36 (0.13- 1.00) 0.049 1.16 (0.37- 3.60) 0.804
Hormone receptor therapy
Yes 47 (52.8) 263 (70.1) 1 (reference) 1 (reference) 21 (46.7) 292 (68.5) 1 (reference) 1 (reference)
No 42 (47.0) 112 (29.9) 1.79 (1.18- 2.71) 0.006 2.43 (1.17- 5.07) 0.018 24 (53.3) 134 (31.5) 2.33 (1.30- 4.18) 0.005 1.51 (0.80- 2.85) 0.201
Radiotherapy

















Table 1 Baseline characteristics of subjects by follow up status (Continued)
No 45 (51.1) 187 (50.3) 0.90 (0.59- 1.37) 0.633 0.96 (0.62- 1.48) 0.843 26 (56.5) 211 (50.0) 1.10 (0.61- 1.97) 0.760 1.12 (0.61- 2.04) 0.723
NOTE Column frequency may be less than total number of subjects due to missing values.
a Disease free survival event (relapse) included locoregional recurrence (n=76), 2nd primary cancer (n=11), and death (n=3) from any cause.
b Adjusted for age, tumor size (≤2cm and >2cm), lymph-node involvement (no and yes), histologic grade (I-II and III), nuclear grade (I-II and III) and ER status (positive and negative), PR status (positive and negative)
and hormone receptor therapy (yes and no.).
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however, the menopausal status were not significantly
different between the groups.
Of the 488 invasive breast cancer patients included in
this study, 323 (66.5%) patients were premenopausal
women, 449 cases patients (92.0%) had ductal carcin-
oma, 37 cases (7.6%) had either lobular, mucinous or
papillary carcinoma, and 2 cases were unknown. Over
83% of all cases (n= 408) had early stage disease (stage I-
IIB).
During a median follow-up of 4.24 years (range, 0.1-
8.3 years) of DFS, there were 76 recurrences, 11 second
primary cancers, and 3 deaths among the 480 patients
diagnosed with stage I-III. In addition, during a median
follow-up of 6.24 years (range, 0.2-9.5 years) of OS, there
were 41 deaths from any cause among the 488 patients.
Table 1 summarized univariate and multivariate–
adjusted HRs for DFS and OR by patients' characteris-
tics. There were significant differences across survival
curves of DFS and OS according to tumor size, lymph-
node involvement, metastasis, histologic grade, nuclear
grade, ER receptor, adjuvant chemotherapy and hormone
receptor therapy (log-rank P< 0.05, data not shown). In
multivariate analysis, tumor size, lymph-node involve-
ment, histologic grade, nuclear grade, ER status, PR sta-
tus, and hormone receptor therapy were remained as
independent and significant prognostic factors for DFS
and tumor size, lymph-node involvement, metastasis,
histologic grade and hormone receptor therapy for OS
(P< 0.20).
Results from association analyses for 40 SNPs and
breast cancer prognosis are presented in Table2. There
were seven SNPs significantly associated with breast
cancer survival. Two SNPs in AGO2 (rs11786030 and
rs2292779) and DICER1 rs1057035 were associated with
both DFS and OS. Two SNPs in HIWI (rs4759659 and
rs11060845) and DGCR8 rs9606250 were associated with
DFS, while DROSHA rs874332 and GEMIN4 rs4968104
were associated with only OS (P< 0.05, Table 2). The
statistical significance was retained after multiple com-
parisons only for the association between AGO2
rs2292779 and OS.
The most significant association was observed for the
AGO2 rs11786030 G allele. The cases with AG/GG gen-
otypes had 2.62-fold increased risk of disease progres-
sion of breast cancer (95% confidence interval (CI),
1.41-4.88) and 2.41-fold increased risk of death (95% CI,
1.05-5.50). The AGO2 rs2292779 was also associated
with poor prognosis of breast cancer. The minor allele
(G) of SNP rs2292779 was associated with 1.42-fold
increased risk of disease progression in dose dependent
manner (95% CI, 1.05-1.87) and the association with the
risk of death was stronger with an adjusted HR of 2.94
in recessive model (95% CI, 1.18-4.35). In addition, theSNP rs1057035 located in 3’UTR of DICER1 was also
associated with both DFS and OS. The TC/CC geno-
types of rs1057035 were associated with 1.72-fold
increased risk of disease progression (95% CI, 1.00-2.99)
and 2.08-fold increased the risk of death.
The DGCR8 rs9606250 and two SNPs in HIWI
(rs4759659 and 11060845) were associated with only
DFS. The variant allele of DGCR8 rs9606250 variant al-
lele (T) was significantly associated DFS with an
adjusted HR of 0.21 (95% CI, 0.05-0.84) in dominant
model. The HIWI rs4759659 variant allele (A) was asso-
ciated with decreased risk of disease progression (per-
allele HR, 0.50; 95% CI, 0.29-0.85), however, rs11060845
variant allele (T) was associated with increased risk of
disease progression.
The DROSHA rs874332 C allele was associated with
increased risk of death in recessive model (adjusted HR
TT/TC vs CC, 2.24; 95% CI, 1.21-4.17) and GEMIN4
rs4968104 A allele was associated with decreased risk of
death in dose dependent manner (per-allele HR, 0.46;
95% CI, 0.21-0.99).
We conducted haplotype analysis for 13 genes other
than p68 and XPO5. We found that common haplotypes
of AGO2 were associated with both DFS and OS
(Table 3). The four most common haplotypes were G-
A-T-C-A, C-A-T-C-G, G-A-T-C-G, and G-A-C-C-A
with the respective frequencies of 37.1%, 26.6%, 19.6%
and 3.5% accounting for 87.1% in all patients. We
found the haplotype of G-A-T-C-G were significantly
increased risk of disease progression and death com-
pared to the most common haplotype of G-A-T-C-A
(adjusted HR, 2.66; 95% CI, 1.49-4.73; P = 0.001 and
adjusted HR, 3.11; 95% CI, 1.34-7.23; P = 0.008, re-
spectively). No significant associations were observed
with haplotype of other genes (data not shown).
We also found cumulative effects of SNPs on DFS and
OS. Compared with subjects carrying 0 to 2 high-risk
genotypes, those carrying 3 and 4–6 high-risk genotypes
had an increased risk of disease progression with an
adjusted HR of 2.16 (95% CI. 1.18-3.93) and 4.47 (95%
CI, 2.45-8.14), respectively (HR for trend, 2.11; P for
trend, 6.11E-07). Similar pattern was observed as for OS,
although the association was stronger than that for DFS
(HR for trend, 2.80; P for trend, 3.30E-05) (Table 4). The
Kaplan-Meier survival function is consistent with the re-
sult of proportional hazard assumption (data not shown).
Discussion
In this study, we found seven SNPs significantly asso-
ciated with breast cancer prognosis and gene-dosage ef-
fect of increasing number of high-risk genotypes on DFS
and OS of breast cancer. Two SNPs in AGO2
(rs11786030 and rs2292779) and DICER1 rs1057035
were associated with both DFS and OS. Two SNPs in
Table 2 Association of SNPs in microRNA biogenesis pathway genes and breast cancer survival
Gene SNP Position Major/
Minor
allele
MAFa Disease-free survival Overall survival
Genetic model aHR (95 % CI) b P FDR P Geneticmodel aHR (95 % CI) c P FDR P
AGO1 rs595055 intron G/A 0.17 REC 1.86 (0.65-5.30) 0.247 0.47 ADD 0.66 (0.36-1.21) 0.181 0.44
rs11263833 intron T/G 0.24 REC 1.35 (0.56-3.27) 0.500 0.61 REC 0.56 (0.13-2.38) 0.430 0.60
AGO2 rs2292779 intron C/G 0.38 ADD 1.42 (1.06-1.92) 0.021 0.27 REC 2.94 (1.52-5.69) 0.001 0.05
rs3864659 intron A/C 0.05 ADD 0.85 (0.44-1.62) 0.619 0.69 DOM 1.11 (0.43-2.85) 0.825 0.93
rs7016981 intron T/C 0.10 ADD 0.77 (0.46-1.30) 0.326 0.49 DOM 1.48 (0.75-2.91) 0.254 0.50
rs7824304 intron C/T 0.05 ADD 0.53 (0.24-1.18) 0.120 0.36 ADD 0.59 (0.20-1.75) 0.340 0.57
rs11786030 3’ UTR A/G 0.48 DOM 2.62 (1.41-4.88) 0.002 0.09 DOM 2.41 (1.05-5.50) 0.037 0.38
DGCR8 rs2073779 intron T/C 0.08 DOM 0.89 (0.50-1.60) 0.706 0.72 ADD 0.92 (0.43-1.97) 0.836 0.93
rs9605062 intron T/C 0.14 ADD 0.65 (0.40-1.06) 0.084 0.34 ADD 0.62 (0.30-1.26) 0.186 0.44
rs9606250 intron A/T 0.05 DOM 0.21 (0.05-0.84) 0.028 0.28 - - - 0.99
DICER1 rs1057035 3’ UTR T/C 0.09 DOM 1.72 (0.99-2.99) 0.054 0.31 DOM 2.08 (1.01-4.28) 0.047 0.38
rs2282265 intron A/G 0.45 REC 1.70 (0.99-2.91) 0.055 0.31 DOM 0.87 (0.44-1.74) 0.700 0.85
DROSHA rs644236 intron C/T 0.31 REC 0.80 (0.41-1.58) 0.517 0.61 ADD 0.73 (0.46-1.15) 0.173 0.44
rs874332 intron T/C 0.47 REC 1.25 (0.76-2.05) 0.382 0.54 REC 2.24 (1.21-4.17) 0.011 0.21
rs7737174 intron G/A 0.46 REC 1.13 (0.69-1.85) 0.639 0.69 REC 0.76 (0.36-1.61) 0.469 0.60
rs10461898 intron A/G 0.23 REC 1.75 (0.68-4.46) 0.244 0.47 ADD 1.44 (0.86-2.41) 0.170 0.44
rs11748548 intron G/A 0.26 DOM 0.79 (0.51-1.24) 0.307 0.49 ADD 0.71 (0.43-1.16) 0.167 0.44
rs16901096 intron C/T 0.21 DOM 0.73 (0.46-1.16) 0.185 0.44 DOM 0.58 (0.30-1.11) 0.098 0.44
FMR1 rs25704 3’ UTR T/C 0.35 DOM 1.27 (0.82-1.97) 0.287 0.49 DOM 1.39 (0.74-2.61) 0.302 0.52
rs28900 intron A/C 0.46 DOM 1.21 (0.75-1.94) 0.443 0.59 DOM 1.63 (0.81-3.29) 0.175 0.44
rs971000 intron C/T 0.33 DOM 1.45 (0.94-2.23) 0.095 0.35 DOM 1.71 (0.92-3.18) 0.089 0.44
GEMIN3 rs197413 V642V G/A 0.39 REC 1.33 (0.78-2.26) 0.299 0.49 REC 0.65 (0.25-1.66) 0.368 0.58
rs17569368 intron A/T 0.09 DOM 1.38 (0.80-2.37) 0.242 0.47 DOM 1.14 (0.54-2.42) 0.727 0.86
GEMIN4 rs7813 C1033R T/C 0.35 ADD 0.77 (0.56-1.07) 0.126 0.36 REC 0.69 (0.27-1.82) 0.459 0.60
rs2740349 N929D A/G 0.13 DOM 0.83 (0.47-1.44) 0.502 0.61 DOM 0.81 (0.37-1.79) 0.604 0.76
rs3744741 Q684R C/T 0.22 REC 1.21 (0.52-2.81) 0.662 0.7 REC 1.83 (0.64-5.28) 0.262 0.50
rs4968104 E593V T/A 0.15 DOM 0.62 (0.36-1.06) 0.078 0.34 ADD 0.46 (0.21-0.99) 0.048 0.38
HIWI rs4759659 intron G/A 0.14 ADD 0.50 (0.29-0.85) 0.011 0.22 ADD 0.67 (0.32-1.39) 0.281 0.51
rs7963072 intron G/A 0.1 REC 1.71 (0.23-12.7) 0.598 0.68 REC 4.30 (0.57-32.5) 0.158 0.44
rs1106042 K527R G/A 0.11 DOM 1.05 (0.61-1.82) 0.859 0.86 DOM 1.04 (0.50-2.16) 0.908 0.95
rs11060845 intron G/T 0.4 ADD 1.36 (1.00-1.85) 0.054 0.31 DOM 1.76 (0.88-3.54) 0.110 0.44
p68 rs1991401 5’ UTR A/G 0.36 ADD 0.87 (0.63-1.20) 0.391 0.54 REC 1.35 (0.60-3.07) 0.467 0.60

















Table 2 Association of SNPs in microRNA biogenesis pathway genes and breast cancer survival (Continued)
rs138462 3’ UTR A/G 0.12 REC 1.60 (0.38-6.69) 0.519 0.61 DOM 0.72 (0.35-1.48) 0.378 0.58
rs12627803 intron T/C 0.21 REC 0.53 (0.15-1.91) 0.329 0.49 DOM 1.27 (0.69-2.33) 0.446 0.60
rs2267390 intron C/T 0.37 REC 0.58 (0.27-1.23) 0.156 0.42 REC 0.45 (0.14-1.47) 0.186 0.44
rs5750609 intron C/T 0.16 REC 0.28 (0.04-2.06) 0.213 0.47 ADD 0.69 (0.37-1.28) 0.245 0.50
RAN rs7958223 intron C/A 0.2 DOM 1.35 (0.88-2.07) 0.176 0.44 REC 2.02 (0.60-6.78) 0.257 0.50
rs10848236 intron G/A 0.16 DOM 1.52 (0.98-2.37) 0.062 0.31 ADD 1.03 (0.58-1.84) 0.909 0.95
XPO5 rs11077 3’ UTR A/C 0.09 ADD 0.56 (0.27-1.18) 0.128 0.36 ADD 0.96 (0.44-2.09) 0.922 0.95
NOTE ADD, additive model; DOM, dominant model; REC, recessive model.
a Major/minor alleles and frequencies as determined by the distribution among all patients.
b Adjusted for age, tumor size (≤2 cm and >2 cm), lymph-node involvement (no and yes), histologic grade (I-II and III), nuclear grade (I-II and III) and ER status (positive and negative), PR status (positive and negative)
and hormone receptor therapy (yes and no).

















Table 3 Association of AGO2 haplotypes and breast cancer survival
Disease-free survival Overall survival
Haplotype Relapse, N (%) No relapse, N (%) aHR (95 % CI) a P Death, N (%) Alive, N (%) aHR (95 % CI) b P
G-A-T-C-A 22 (25.9) 152 (39.9) 1 (reference) 9 (20.9) 167 (38.8) 1 (reference)
C-A-T-C-G 24 (28.2) 100 (26.3) 1.29 (0.71-2.34) 0.411 13 (30.2) 113 (26.2) 1.73 (0.72-4.13) 0.217
G-A-T-C-G 27 (31.8) 63(16.5) 2.66 (1.49-4.73) 0.001 15 (34.9) 78 (18.1) 3.11 (1.34-7.23) 0.008
G-A-C-C-A 5 (5.9) 12 (3.2) 1.76 (0.66-4.71) 0.262 2 (4.65) 16 (3.7) 2.22 (0.47-10.6) 0.316
Others 7 (8.24) 54 (14.2) 0.66 (0.28-1.56) 0.343 4 (9.3) 57 (13.2) 1.02 (0.31-3.33) 0.978
Total 85 (100) 381 (100) 43 (100) 431 (100)
NOTE The AGO2 haplotype was composed of five SNPs in order of rs2292779, rs3864659, rs7016981, rs7824304, rs11786030.
a Adjusted for age, tumor size (≤2 cm and >2 cm), lymph-node involvement (no and yes), histologic grade (I-II and III), nuclear grade (I-II and III) and ER status
(positive and negative), PR status (positive and negative) and hormone receptor therapy (yes and no).
b Adjusted for age, tumor size (≤2 cm and >2 cm), lymph-node metastasis (no and yes), metastasis (no and yes), histologic grade (I-II and III), and hormone
receptor therapy (yes and no).
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rs9606250 were associated with DFS, while DROSHA
rs874332 and GEMIN4 rs4968104 were associated with
only OS. Furthermore, some specific AGO2 haplotype
also associated with both DFS and OS.
The AGO2 plays a key role in miRNA-mediated gene
silencing as a component of the miRNA-induced silen-
cing complex that directly binds miRNAs and mediates
cleavage of target mRNA [25]. There are emerging evi-
dence from in vitro analysis and clinical samples that ab-
normal expression or enzymatic function of AGO2 is
associated with cancer development and its progression.
In breast cancer cell lines, it was shown that the overex-
pression of AGO2 could induce the transformed pheno-
type [26]. Moreover, the variations in genomic structure
of AGO2, such as copy number change or frameshift





Cases, Na (%) Relapse
0-2 163 (35.4) 18 (
3 188 (40.9) 32 (
4-6 109 (23.7) 34 (
Ptrend
Cases, Na (%) Death
0-2 6 (14.6) 124
3 12 (29.3) 214
4-5 23 (56.1) 132
Ptrend
NOTE Unfavorable genotypes were defined as rs2292779 (GG), rs11786030 (AG+GG),
(TT) for disease-free survival and rs2292779 (GG), rs11786030 (AG+GG), rs1057035 (TC
a Due to excluding the subject which has at least one missing genotype informatio
for overall survival.
b Adjusted for age, tumor size (≤2 cm and >2 cm), lymph-node involvement (no an
(positive and negative), PR status (positive and negative) and hormone receptor the
c Adjusted for age, tumor size (≤2 cm and >2 cm), lymph-node involvement (no an
receptor therapy (yes and no).cancers including multiple myeloma, gastric and colo-
rectal cancer [27,28].
We observed that variant alleles of rs2292779 and
rs11786030 in AGO2 were commonly associated with
poor DFS and poor OS. In our previous study, we
reported SNP rs3864659 in AGO2 is associated with the
reduction of breast cancer risk. However, we did not ob-
serve the significant association with breast cancer sur-
vival for rs3864659 implying its different role in tumor
development and survival in breast cancer patients. The
rs2292779 G allele was more significantly and strongly
associated with OS than DFS, while the effect sizes of
rs11786030 were similar between OS and DFS. Further-
more, the haplotype containing minor alleles of both
SNPs (rs2292779 and rs11786030) was also significantly
associated with both DFS and OS showing slightly larger
effect than those of estimated from single SNP. Theable genotypes in miRNA biogenesis pathway genes and
Disease-free survival
, N (%) aHRb (95 % CI) P
21.4) 1 (reference)
38.1) 2.16(1.18- 3.93) 1.22E-02
40.5) 4.47(2.45- 8.14) 9.87E-07
2.11(1.57- 2.83) 6.11E-07
Overall survival
, N (%) aHRc (95 % CI) P
(26.4) 1 (reference)
(45.5) 1.21(0.44- 3.30) 7.13E-01
(28.1) 5.34(2.12-13.49) 3.93E-04
2.80(1.72- 4.55) 3.30E-05
rs9606250 (AA+AT), rs1057035 (TC+CC), rs4759659 (GG+GA), and rs11060845
+CC), rs874332 (CC), and rs4968104 (TT) for overall survival, respectively.
n in this analysis, all subjects are less than 480 for disease-free survival and 488
d yes), histologic grade (I-II and III), nuclear grade (I-II and III) and ER status
rapy (yes and no).
d yes), metastasis (no and yes), histologic grade (I-II and III), and hormone
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http://www.biomedcentral.com/1471-2407/12/195AGO2 rs2292778 was not genotyped in our study, but it
is a perfect proxy for AGO1 rs2292779, based on the
HapMap Chinese in Beijing (CHB) (r2 = 0.94) and
Japanese in Tokyo (JPT) (r2 = 0.95) and even in CEPH
European ancestry (CEU) (r2 = 1.00). It is intriguing that
the AGO2 rs2292778 is highly evolutionary conserved
allele (conservation score = 0.992) although it resides
outside the coding region of AGO2 suggesting potential
functional effect of these variants [25]. However, it
should be answered whether the function or expression
level of AGO2 is regulated via proxy or identified SNP
through experimental study.
The SNP rs9606250 in DGCR8 was found to be asso-
ciated with longer DFS. As for the association with OS,
however, we could not evaluate the effect of rs9606250
on OS due to low frequency of minor allele homozygote.
DGCR8 (Pasha) is a double stranded RNA-binding pro-
tein involved in processing of primary precursor of miR-
NAs into the pre-miRNAs as a component of multi-
protein complex with RNAse III enzyme DROSHA
(RNASEN). The possible role of DGCR8 gene in the clin-
ical outcome of breast cancer has been recently reported
[25]. It was shown that impaired miRNA processing
through knockdown of DGCR8 facilitates breast cancer
cell invasion. Interestingly, both rs9605062 and
rs9606250 identified in DGCR8 is in high LD with
rs9606232 (CHB and JPT, r2 = 1.00; CEU, r2 = 0.83),
which is located at a conserved transcription-binding
site of DGCR8. Thus, it is plausible that the level or the
timing of gene expression might be regulated by these
variants, although more detailed functional studies
should provide evidence for the underlying mechanism.
In previous studies, three SNPs in DGCR8 were asso-
ciated with OS of ovarian cancer consistent with our re-
sult [17], although there is no significant association
between the genetic variants in DGCR8 and survival of
patients with colorectal cancer [15], head and neck can-
cer [18] and renal cell carcinoma [16].
We also observed the variant allele of HIWI rs4759659
was also associated with longer DFS, although it was not
associated with OS. In addition, HIWI rs11060845 was
associated with increased risk of disease progression in
the present study, while this SNP was associated with
risk reduction in breast cancer susceptibility in our pre-
vious study implicating the difference effect of the same
variant on cancer development and progression. HIWI
(PIWI1) is suggested to play an important role in stem
cell renewal, division, germ cell proliferation, RNA silen-
cing and translational regulation [29]. In addition, HIWI
expression has been shown to be associated with tumor
development including gastric cancer [30] and pancreas
adenocarcinoma [31]. Furthermore, the expression level
of HIWI has been shown to be associated with cancer
survival in esophageal squamous cancer cells [32] andsoft-tissue sarcoma [21]. It is notable that HIWI is sig-
nificantly overexpressed in several metastatic tumor tis-
sues compared to benign hyperplasia or chronic
inflammation lesion, and the expression is positively cor-
related with Ang-2 and Tie-2 which play a key role in
angiogenesis [33]. However, further study is warranted
to prove whether the identified variant leads to
decreased expression of HIWI gene and whether the ef-
fect of this variant on breast cancer microinvasion or
metastasis is mediated by angiogenic pathway.
We also found the variant allele of DROSHA rs874332
was associated with poor OS in breast cancer. DROSHA
(RNASEN) is RNAse III enzyme mediating processing of
pri-miRNAs into pre-miRNAs with DGCR8. The signifi-
cance of aberrant expression levels of DROSHA as a po-
tential prognostic factor has been substantiated in
several studies on esophageal cancer [34], cervical neo-
plastic progression [35], ovarian cancer [36], and neuro-
blastoma [37] .
In breast cancer, down regulation in DROSHA and/or
DICER was preferentially observed in distinct subgroups
of breast cancer [38] . In addition, the haplotypes of
DROSHA and DICER, but not individual SNP, were
associated with altered survival and recurrence of renal
cancer carcinoma [16]. Through in vitro functional
study, Noh et al. demonstrated that less efficient miRNA
processing caused by knockdown of DROSHA, DICER
and DGCR8 is responsible for reduced levels of mature
forms of tumor-suppressive miRNAs, and finally facili-
tates breast cancer cell invasion by upregulating the ex-
pression of urokinase-type plasminogen activator (uPA)
[39]. Considering that DROSHA rs642321, the proxy of
rs874332 (CHB r2 = 0.93; JPT, r2 = 0.87 and CEU,
r2 = 0.82), is located in the 3’-untranslated region (UTR)
of DROSHA and is a predicted miRNA binding site
(http://www.microrna.org/microrna/home.do), it is
plausible that rs874332 could be associated with transla-
tional repression and/or mRNA destabilization of
DROSHA through miRNA-mRNA interaction.
We performed polygenic risk model analysis to investi-
gate the cumulative effects of SNPs on breast cancer sur-
vival. By combining six SNPs for DFS and five SNPs for
OS, we observed a strong dose–response trend toward
an increasing risk of disease progression or death with
an increasing number of high-risk genotypes. This cu-
mulative effect of variants in miRNA biogenesis pathway
genes on breast cancer survival is consistent with the
notion that the germline genetic variation could be asso-
ciated with cancer progression and survival via polygenic
manner.
Although the present study included tagging SNPs in
most currently known miRNA biogenesis pathway genes,
future studies should investigate the comprehensive list
of genetic variants in miRNA genes and target binding
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deregulation of miRNA network caused potentially by
the genetic variants is implicated in breast cancer
prognosis.
There are several limitations in this study. We could
not evaluate the association between the selected SNPs
and breast cancer specific mortality because the data for
the cause of death were not available. Thus, the results
on the association with the OS must be interpreted cau-
tiously and need to be confirmed in study to investigate
the association with breast cancer specific survival. The
primary limitation is the limited power to detect the po-
tential effects of genetic variants on the breast cancer
prognosis, especially for the several SNPs with low
minor allele frequencies. This study has only 1 to 66% of
the statistical power to detect the effect sizes of 1.10 to
1.40 with the current sample size (Bonferroni corrected
p-value = 0.001). Along with the limited power, some of
the SNPs we identified might be attained by chance find-
ing given the loss of robustness after multiple compari-
son adjustments. Furthermore, the risk profiles of
genetic variants identified from this study could be man-
ifested differently in different ethnic populations assum-
ing the differences in MAF and underlying genomic
structure, and interactions of environmental factors and
other modifiers could have an effect on the penetrance
of these SNPs.
Conclusions
We evaluated the comprehensive list of tagging SNPs in
most currently known miRNA biogenesis pathway genes
and we identified the associations between several puta-
tive genetic variants in miRNA biogenesis pathway genes
and breast cancer survival. To the best of our know-
ledge, this is the first study to provide evidence suggest-
ing that common genetic variants in miRNA biogenesis
pathway genes may affect the breast cancer survival, in-
dividually and jointly. To more powerfully elucidate this
risk-conferring effect of any SNP observed in this study,
further epidemiological studies in independent and large
number of subjects and functional studies need to valid-
ate our findings.
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